내과계 중환자실 약료 서비스 도입과 약물상호작용 모니터링
Initiation of Pharmaceutical Care Service in Medical Intensive Care Unit with Drug Interaction Monitoring Program
0
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Objective: It is to evaluate the drug interaction monitoring program as a pilot project to develop a pharmaceutical care model in a medical intensive care unit and to analyze the influencing factors of drug interactions. Method: Electronic medical records were retrospectively investigated for 116 patients who had been hospitalized in a medical intensive care unit from October to December in 2014. The prevalence of adverse reaction with risk rating higher than ‘D’ was investigated by Lexi-Comp® Online database. The factors related with potential drug interaction and with treatment outcomes were analyzed. Results: The number of patients with a potential interaction of drug combination was 92 (79.3%). Average ages, the length of stay in the intensive care unit and the numbers of prescription drugs showed significant differences between drug interaction group and non-drug interaction group. Opioids (14.4%), antibiotics (7.2%), and diuretics (7.2%) were most responsible drug classes for drug interactions and the individual medications included furosemide (6.4%), tramadol (4.9%), and remifentanil (4.5%). There were 950 cases with a risk rating of ‘C’ (84.6%), 142 cases with a risk rating of ‘D’ (12.6%), and 31 cases with a risk rating of ‘X’ (avoid combination) (2.8%). The factors affecting drug interactions were the number of drugs prescribed (p < 0.0001) and the length of stay at intensive care unit (p < 0.01). The patients in intensive care unit showed a high incidence of adverse reactions related to potential drug interaction. Therefore, drug interaction monitoring program as a one of pharmaceutical care services was successfully piloted and it showed to prevent adverse reaction and to improve therapeutic outcomes. Conclusion: Active participation of a pharmacist in the drug management at the intensive care unit should be considered.
Abstract
Objective: It is to evaluate the drug interaction monitoring program as a pilot project to develop a pharmaceutical care model in a medical intensive care unit and to analyze the influencing factors of drug interactions. Method: Electronic medical records were retrospectively investigated for 116 patients who had been hospitalized in a medical intensive care unit from October to December in 2014. The prevalence of adverse reaction with risk rating higher than ‘D’ was investigated by Lexi-Comp® Online database. The factors related with potential drug interaction and with treatment outcomes were analyzed. Results: The number of patients with a potential interaction of drug combination was 92 (79.3%). Average ages, the length of stay in the intensive care unit and the numbers of prescription drugs showed significant differences between drug interaction group and non-drug interaction group. Opioids (14.4%), antibiotics (7.2%), and diuretics (7.2%) were most responsible drug classes for drug interactions and the individual medications included furosemide (6.4%), tramadol (4.9%), and remifentanil (4.5%). There were 950 cases with a risk rating of ‘C’ (84.6%), 142 cases with a risk rating of ‘D’ (12.6%), and 31 cases with a risk rating of ‘X’ (avoid combination) (2.8%). The factors affecting drug interactions were the number of drugs prescribed (p < 0.0001) and the length of stay at intensive care unit (p < 0.01). The patients in intensive care unit showed a high incidence of adverse reactions related to potential drug interaction. Therefore, drug interaction monitoring program as a one of pharmaceutical care services was successfully piloted and it showed to prevent adverse reaction and to improve therapeutic outcomes. Conclusion: Active participation of a pharmacist in the drug management at the intensive care unit should be considered.
참고문헌 (10)
- Hasan SS., "Impact of pharmacists' intervention on identification and management of drug-drug interactions in an intensive care setting", Singapore Med J, 53(8), pp.526~531 (2012)
- Smithburger PL., "Drug-drug interactions in the medical intensive care unit : an assessment of frequency, severity and the medications involved", Int J Pharm Pract, 20(6), pp.402~408 (2012)
- LeBlanc JM., "International critical care hospital pharmacist activities", Intensive Care Med, 34(3), pp.538~542 (2008)
- Kim HA, "A Study on the Improvement of Drug Safety for Pharmaceutical Care Disparities in Korea", In: Fall Symposium of Korean Academy of Social & Managed Care Pharmacy (2014), Republic of Korea
- "Lexi-interactTM"[URL]
- "Common terminology criteria for adverse events v4.0 (CTCAE)"[URL]
- Rivkin A., "Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients", J Crit Care, 26(1), pp.104.e1~104.e6 (2011)
- Cash JJ, "Alert fatigue", Am J Health-Syst Pharm, 66(23), pp.2098~2101 (2009)
- Kreutz RP., "Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement : The Clopidogrel Medco Outcomes Study", Pharmacotherapy, 30(8), pp.787~796 (2010)
- Fischer JR., "Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents", Ann Pharmacother, 30(12), pp.1437~1445 (1996)